Nirsevimab Library
This is a collection of current resources related to Nirsevimab.
New and Emerging Passive Immunization Strategies for the Prevention of RSV Infection During Infancy
This article discusses new ways to protect babies from RSV, a virus causing lung infections. Two methods were approved in 2023: one uses a long-lasting …
Ask aRCie
RSV Prevention Update: ACIP/AAP Recommendations for Nirsevimab in Infants and RSV Vaccine in Pregnancy
These presentation slides provide information for physicians about recommendations for nirsevimab for prevention of serious lower respiratory tract infection from respiratory syncytial virus (RSV) in …
Uptake of Maternal RSV Vaccination and Infant Nirsevimab Among Infants Born October 2023 to March 2024
2025
· Kaiser Permanente
The article investigates the uptake of maternal RSV vaccination and infant nirsevimab among infants born from October 2023 to March 2024 within Kaiser Permanente Northern …
Efficacy of Nirsevimab Against Respiratory Syncytial Virus Lower Respiratory Tract Infections in Preterm and Term Infants, and Pharmacokinetic Extrapolation to Infants With Congenital Heart Disease and Chronic Lung Disease: A Pooled Analysis of Randomised Controlled Trials
2023
· Children's Hospital Colorado,
· University of the Witwatersrand,
· Northwestern University,
· Dr. Georgi Stranski University Hospital,
· Quironsalud Madrid University Hospital,
· State University of New York - Upstate Medical University
This article describes a study on the effectiveness of nirsevimab in preventing respiratory syncytial virus (RSV) infections in infants. It focuses on both preterm and …
Review and Update of Active and Passive Immunization Against Respiratory Syncytial Virus
This article reviews ways to protect against respiratory syncytial virus (RSV). It describes both active and passive immunization methods. Active immunization involves vaccines that help …
Impact of Nirsevimab Prophylaxis on Paediatric Respiratory Syncytial Virus (RSV)-Related Hospitalisations During the Initial 2023/24 Season in Luxembourg
2024
· European Centre for Disease Prevention and Control (ECDC),
· European Centre for Disease Prevention and Control (ECDC),
· Centre Hospitalier de Luxembourg
This study examines the impact of nirsevimab, a new antibody, on reducing RSV-related hospitalizations in Luxembourg during the 2023/24 season. After its introduction, neonatal coverage …
Does Nirsevimab Prevent Lower Respiratory Infections Caused by Respiratory Syncytial Virus?
2024
· University of Virginia
This study examines nirsevimab, a monoclonal antibody that helps prevent respiratory syncytial virus (RSV) infections in infants. It found that one injection of nirsevimab significantly …
Outpatient Respiratory Syncytial Virus Infections and Novel Preventive Interventions
2024
· University Medical Center Utrecht,
· Respiratory Syncytial Virus NETwork (ReSViNET) Foundation
This article focuses on respiratory syncytial virus (RSV) infections that occur outside of hospitals. It describes new ways to prevent these infections, which are common …
Rapid Review Showed That Real-World Results on How Nirsevimab Prevented Respiratory Syncytial Virus Hospitalisations Were Similar to Randomised Trials
This brief report describes a study on nirsevimab, a treatment to prevent RSV hospitalizations in infants. Real-world results from studies in Luxembourg, Spain, and the …
Effectiveness of Nirsevimab Immunoprophylaxis Against Respiratory Syncytial Virus-Related Outcomes in Hospital and Primary Care Settings: A Retrospective Cohort Study in Infants in Catalonia (Spain)
This study in Catalonia, Spain looks at the effectiveness of nirsevimab, a monoclonal antibody for RSV, in infants under 6 months old. The study shows …